FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:64-65 January 1, 1998 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Rosenbaum, M. Related Article by Rosenbaum, M. PubMed Citation

To the Editor: In their article on obesity, Rosenbaum et al. (Aug. 7 issue)¹ characterize sibutramine, currently undergoing regulatory review as a drug for the treatment of obesity, as having both catecholaminergic and serotonergic agonist effects. Sibutramine, in fact, is not an agonist at catecholamine or serotonin receptors but instead acts by inhibiting the reuptake of serotonin and norepinephrine at central synapses. Thus, sibutramine's mode of action is similar to that of other monoamine-reuptake inhibitors such as venlafaxine (an inhibitor of serotonin and norepinephrine reuptake) and fluoxetine (a selective serotonin-reuptake inhibitor). The mode of action of drugs that alter appetite . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Michaud, J. L., Boucher, F., Melnyk, A., Gauthier, F., Goshu, E., Levy, E., Mitchell, G. A., Himms-Hagen, J., Fan, C.-M. (2001). Sim1 haploinsufficiency causes hyperphagia, obesity and reduction of the paraventricular nucleus of the hypothalamus. Hum Mol Genet 10: 1465-1473 [Abstract] [Full Text]